Pneumococcal Vaccine – Sanofi PSK00029

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of this study is to compare three different lots of PCV21 when administered with the full schedule. The safety profile will be compared with Prevnar 20® (an already available pneumococcal vaccine).

PCV21 has already been tested in several other studies. None of the conducted studies resulted in any safety concerns. PCV21 was well-tolerated in adults and children.

Your child may be able to join the study if he/she meets these and other criteria:

• 42 to 89 days old
• Healthy as determined by medical evaluation
• Born at full term (≥37 weeks) and with a birth weight ≥2.5 kg or born after 28 weeks and with a birth weight ≥1.5 kg